BACKGROUND: The p53 antisense oligonucleotide cenersen has been shown to sensitize acute myeloid leukemia (AML) stem cells to DNA damaging agents. METHODS: To determine whether cenersen merits testing in larger efficacy studies, an exploratory study of cenersen in combination with idarubicin either alone or with 1 of 2 doses of cytarabine was performed in first-salvage AML patients. Patients who either had failed to respond to a single induction course or had responded to induction but relapsed within 12 months were enrolled. Stopping rules based on an expected 14% complete response (CR) rate were applied to each treatment arm. RESULTS: Fifty-three patients were treated, and none of the arms was terminated for lack of activity. Nearly all patients received a single course unless they responded. Ten of the 53 (19%) patients responded (8 CR and 2 CR with incomplete platelet recovery). There was a positive trend for a better response rate with increasing intensity of chemotherapy in the patients refractory to front-line treatment compared with those who had relapsed previously. One-third (17/53) of the patients received cenersen inhibitors (acetaminophen and/or high dose antioxidants) during treatment, and none of these responded to treatment. No unique toxicity was attributed to cenersen. CONCLUSION: The results of this study suggested that the combination of cenersen with chemotherapy may have clinical efficacy, and additional studies are warranted to explore its full potential.
RCT Entities:
BACKGROUND: The p53 antisense oligonucleotide cenersen has been shown to sensitize acute myeloid leukemia (AML) stem cells to DNA damaging agents. METHODS: To determine whether cenersen merits testing in larger efficacy studies, an exploratory study of cenersen in combination with idarubicin either alone or with 1 of 2 doses of cytarabine was performed in first-salvage AMLpatients. Patients who either had failed to respond to a single induction course or had responded to induction but relapsed within 12 months were enrolled. Stopping rules based on an expected 14% complete response (CR) rate were applied to each treatment arm. RESULTS: Fifty-three patients were treated, and none of the arms was terminated for lack of activity. Nearly all patients received a single course unless they responded. Ten of the 53 (19%) patients responded (8 CR and 2 CR with incomplete platelet recovery). There was a positive trend for a better response rate with increasing intensity of chemotherapy in the patients refractory to front-line treatment compared with those who had relapsed previously. One-third (17/53) of the patients received cenersen inhibitors (acetaminophen and/or high dose antioxidants) during treatment, and none of these responded to treatment. No unique toxicity was attributed to cenersen. CONCLUSION: The results of this study suggested that the combination of cenersen with chemotherapy may have clinical efficacy, and additional studies are warranted to explore its full potential.
Authors: Stephen Hsu; Kajuana Farrey; John Wataha; Jill Lewis; James Borke; Baldev Singh; Haiyan Qin; Carol Lapp; David Lapp; Tuan Nguyen; George Schuster Journal: Anticancer Res Date: 2005 Jan-Feb Impact factor: 2.480
Authors: L Girnita; A Girnita; B Brodin; Y Xie; G Nilsson; A Dricu; J Lundeberg; J Wejde; A Bartolazzi; K G Wiman; O Larsson Journal: Cancer Res Date: 2000-09-15 Impact factor: 12.701
Authors: P G Komarov; E A Komarova; R V Kondratov; K Christov-Tselkov; J S Coon; M V Chernov; A V Gudkov Journal: Science Date: 1999-09-10 Impact factor: 47.728
Authors: P Wlodarski; M Wasik; M Z Ratajczak; C Sevignani; G Hoser; J Kawiak; A M Gewirtz; B Calabretta; T Skorski Journal: Blood Date: 1998-04-15 Impact factor: 22.113
Authors: M R Bishop; P L Iversen; E Bayever; J G Sharp; T C Greiner; B L Copple; R Ruddon; G Zon; J Spinolo; M Arneson; J O Armitage; A Kessinger Journal: J Clin Oncol Date: 1996-04 Impact factor: 44.544
Authors: Susan O'Brien; David A Rizzieri; Norbert Vey; Farhad Ravandi; Utz O Krug; Mikkael A Sekeres; Mike Dennis; Adriano Venditti; Donald A Berry; Tove Flem Jacobsen; Karin Staudacher; Trygve Bergeland; Francis J Giles Journal: Br J Haematol Date: 2012-06-15 Impact factor: 6.998
Authors: Gisela Caceres; Kathy McGraw; Bon Ham Yip; Andrea Pellagatti; Joseph Johnson; Ling Zhang; Kenian Liu; Lan Min Zhang; William J Fulp; Ji-Hyun Lee; Najla H Al Ali; Ashley Basiorka; Larry J Smith; F Joseph Daugherty; Neil Littleton; Richard A Wells; Lubomir Sokol; Sheng Wei; Rami S Komrokji; Jacqueline Boultwood; Alan F List Journal: Proc Natl Acad Sci U S A Date: 2013-09-16 Impact factor: 11.205